Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.49 |
| ▸ | MAOA | P21397 | 8/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10196140 | 0.92 | CALML3 (0.48) | CALML3MAOATHRBGRM2 | |
| SCHEMBL10196130 | 0.90 | CALML3 (0.58) | CALML3MAOATHRBMAOB | |
| SCHEMBL10196138 | 0.87 | CALML3 (0.49) | CALML3MAOAGRM2 | |
| SCHEMBL10259390 | 0.86 | MAOA (0.60) | CALML3MAOATHRBMAOB | |
| SCHEMBL15502614 | 0.85 | CALML3 (0.43) | CALML3MAOATHRB | |
| SCHEMBL10196122 | 0.85 | CALML3 (0.64) | CALML3MAOAMAOB | |
| SCHEMBL10196162 | 0.80 | MAOA (0.52) | CALML3MAOAGRM2MAOB | |
| SCHEMBL10196131 | 0.78 | CALML3 (0.67) | CALML3MAOAMAOB | |
| SCHEMBL10258874 | 0.78 | MAOA (0.61) | CALML3MAOATHRBMAOB | |
| SCHEMBL10196113 | 0.77 | CALML3 (0.67) | CALML3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | RIB-X PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | CALML3 3842/4885MAOA 872/4885THRB 4398/4885 |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | PCNA, AADAC, MIF | CALML3 3842/4885MAOA 872/4885THRB 4398/4885 |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | PCNA, AADAC, MIF | CALML3 3842/4885MAOA 872/4885THRB 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.